Reveal Biosciences, a Global Pathology AI Leader, Raises Series A Funding Led by Intel Capital
Summary
Reveal is focused on improving global healthcare by creating a new generation of objective, data-powered pathology to characterize and detect disease. “AI is an accelerating technology within healthcare imaging that has already demonstrated significant potential to impact research and benefit patients,” said Naveen Rao, corporate vice president and General Manager of the Artificial Intelligence Products Group at Intel Corporation.” Senior Director Ranjeet Alexis led the investment for Intel Capital and will join Reveal’s board. Reveal Biosciences is focused on improving global healthcare by creating a new generation of objective, data-powered pathology to characterize and detect disease. Our proprietary deep-learning platform, ImageDx™, delivers pathologists and scientists a novel class of actionable, quantitative data to advance research and enhance patient care. This advanced laboratory uniquely positions the company to deliver high performing pathology artificial intelligence algorithms at scale.